Compare Gartner Inc (IT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Sana Biotechnology Inc — how do they compare? Gartner Inc trades at $191.18 (market cap $12.34B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Gartner Inc is far larger — about 14.7× Sana Biotechnology Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Sana Biotechnology Inc for 23 Days on average.
| IT | SANA | |
|---|---|---|
Market Cap | $12.34B | $836.71M |
Volume | 919,809 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $258.17 | $5.92 |
52-Week Low | $125.68 | $2.68 |
Typical Hold Time | 64 Days | 23 Days |
Enterprise Value | $14.08B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $191.02, up 2.83% with a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Financials show strong profitability with a 69.63% gross margin and 113.58% ROE, though net income declined in 2025. Recent news highlights AI advisory demand and Gartner's industry leadership, driving positive sentiment.
Outlook remains supported by robust contract value and AI-driven consulting growth, but risks include a high P/B ratio of 160.06 and a shareholder investigation. Analyst consensus is mixed with a $174.63 price target below the current price, suggesting caution despite bullish technicals.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
